We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Oral Yeasts from Cancer Patients Identified by MALDI-TOF

By LabMedica International staff writers
Posted on 22 Jan 2018
Print article
Image: Colonies of different species of Candida after growing for 48 hours at 37 °C in CHROMagar Candida medium supplemented with Pal\'s agar (Photo courtesy of the American Society of Microbiology).
Image: Colonies of different species of Candida after growing for 48 hours at 37 °C in CHROMagar Candida medium supplemented with Pal\'s agar (Photo courtesy of the American Society of Microbiology).
The most predominant yeasts isolated from oral colonization and infections are Candida species that are the most important opportunistic fungal pathogens in humans and cause mucosal to deep-seated candidiasis. Opportunistic infections due to Candida species occur frequently in cancer patients because of their inherent immunosuppression.

The incidence of mild to severe fungal infections (FI) has dramatically increased in the last several decades, especially in patients infected with human immunodeficiency virus (HIV), those that use prolonged broad-spectrum antibiotics, patients undergoing hematopoietic stem cell transplantation (HSCT), and those receiving intensive chemo- and /or radiotherapy.

Scientists at Mazandaran University of Medical Sciences (Sari, Iran) obtained 350 oral swab samples from cancer patients undergoing intensive chemotherapy, namely 210 (60%) males and 140 (40%) females and ranging 17 to 88 years in age with and without sign and symptoms of oral infection, including white plaque, erythematous and ulcerative lesions, dryness, pain, altered taste sensation and halitosis.

Specimens from cotton swabs were initially inoculated on malt extract agar supplemented with chloramphenicol and CHROMagar Candida medium. Strains were preliminarily identified using conventional methods, such as germ tube tests, formation of pseudohyphae, production of chlamydospores and carbohydrate assimilation tests using the ID 32 C kit. All strains were identified by polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) and using the amplified Hyphal wall protein 1(HWP1) gene to distinguish members of the C. albicans complex. Matrix Assisted Laser Desorption/Ionization-time-of-flight mass spectrometer (MALDI-TOF M)S-based identification of all yeast and yeast-like isolates was performed according to Bruker Daltonics.

The scientists reported that among 162 yeasts and yeast-like fungi isolated from the oral cavity of cancer patients, Candida albicans was the most common species (50.6%), followed by Candida glabrata (24.7%), Pichia kudriavzevii (Candida krusei (9.9%)), Candida tropicalis (4.3%), Candida dubliniensis (3.7%), Kluyveromyces marxianus (Candida kefyr (3.7%)) and Candida parapsilosis (1%). Oral colonization by C. albicans, non-albicans Candida species and uncommon yeasts were as follow; 55%, 44% and 1%, whereas oral infection due to C. albicans was 33.3%, non-albicans Candida species 60.6%, and uncommon yeasts 6.1%.

The authors concluded that the incidence of oral candidiasis was higher amongst patients with hematological malignancies. The majority of oral infections were caused by non-albicans Candida species which were often more resistant to anti-fungal agents. Their findings suggest that anidulafungin should be used as antifungal of choice for prophylaxis in clinically high-risk patients with documented oral colonization or infection. The study was published on January 8, 2018, in the journal BMC Infectious Diseases.

Related Links:
Mazandaran University of Medical Sciences

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Glucagon-Like Peptide-1 Assay
Total GLP-1 ELISA Kit
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.